Pharmacokinetics of Telavancin in Normal and Obese Subjects

Trial Profile

Pharmacokinetics of Telavancin in Normal and Obese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Telavancin (Primary)
  • Indications Bacteraemia; Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Osteomyelitis; Skin and soft tissue infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 25 Apr 2017 Results assessing pharmacokinetics of fixed dose telavancin presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 25 Apr 2017 According to a Theravance Biopharma media release,data from this trial was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
    • 18 Apr 2017 According to a Theravance Biopharma media release,data fro this trial will be presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top